Arriva raises $6M for respiratory work

Alameda, CA-based Arriva Pharmaceuticals has rounded up $6 million in funding to advance its work on anti-inflammatory therapies for treating respiratory disease. The round was led by Nordic Biotech; MPM BioVentures also participated. CEO Sue Preston said the funding will be used to develop the company's recombinant
alpha-one antitrypsin for hereditary emphysema.

- see this release

PLUS: With help from Domain Associates, San Diego's Obalon Therapeutics has secured $4.7 million of a 7.7 million first round. Item

Related Articles:
Biotech, emerging markets are big VC targets. Report
Serial investors: Comforting figures for VC backers. Report
VC adds billions in its pursuit of biotech ventures. Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.